High Cut-off Value of a Chimeric TSH Receptor (Mc4)-based Bioassay May Improve Prediction of Relapse in Graves' Disease for 12 months

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 Jun 28

PMID 24968734

Citations 6

Authors

Sena Hwang

Dong Yeob Shin

Mi Kyung Song

Eun Jig Lee

Affiliations

Soon will be listed here.

Abstract

There are scarce reports regarding a functional prognostic value of thyroid-stimulating autoantibody (TSAb) levels using a thyroid-stimulating hormone receptor chimera (Mc4) in Graves' disease (GD) in iodine sufficient area. The aim of this study was to investigate whether Mc4-TSAb can predict GD remission/relapse after antithyroid drug (ATD) treatment and to compare Mc4-TSAb with a binding assay using M22 monoclonal antibody (M22-TRAb) in GD patients. We retrospectively reviewed the results of M22-TRAb and Mc4-TSAb in GD patients treated with ATD for 12 months. GD patients who underwent ATD treatment for at least 12 months were included. We compared the predictive values of M22-TRAb and Mc4-TSAb for GD remission and relapse. Of the 92 patients, 60 (65.2%) achieved remission and 32 (34.8%) relapsed within 12 months. In receiver operating characteristic analysis, there were no significant differences in the area under the curves (AUCs) between Mc4-TSAb [AUC=0.79 (95% CI 0.69-0.89)] and M22-TRAb [AUC=0.69 (95% CI 0.58-0.81)]. The optimal predictive cut-off values of M22-TRAb and Mc4-TSAb were 2.23 IU/L and 230%, respectively. At a high Mc4-TSAb cut-off, the better specificity of 85.0% and positive predictive value (PPV) of 69.0% were shown compared with those at the best cut-off for M22-TRAb. In conclusion, a high cut-off for an Mc4 assay may improve the predictive value of relapse with superior specificity and PPV compared with M22-TRAb in treated GD.

Citing Articles

Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves' disease.

Yao P, Xie Y, Wang Y, Liang C, Huang B Front Endocrinol (Lausanne). 2024; 15:1487490.

PMID: 39669491 PMC: 11634614. DOI: 10.3389/fendo.2024.1487490.

Thyroid-Stimulatory Antibody as a Predictive Factor for Graves' Disease Relapse.

da Silva Santos T, Oliveira J, Freitas C, Couto de Carvalho A Cureus. 2022; 14(2):e22190.

PMID: 35178331 PMC: 8843073. DOI: 10.7759/cureus.22190.

The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease.

Zhou Y, Zhou M, Qi Y, Wang W, Chen X, Wang S Ther Adv Endocrinol Metab. 2021; 12:20420188211044943.

PMID: 34603682 PMC: 8481717. DOI: 10.1177/20420188211044943.

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence.

Liu J, Fu J, Xu Y, Wang G Int J Endocrinol. 2017; 2017:3813540.

PMID: 28529524 PMC: 5424485. DOI: 10.1155/2017/3813540.

Bioassays for TSH Receptor Autoantibodies, from FRTL-5 Cells to TSH Receptor-LH/CG Receptor Chimeras: The Contribution of Leonard D. Kohn.

Giuliani C, Saji M, Bucci I, Napolitano G Front Endocrinol (Lausanne). 2016; 7:103.

PMID: 27504107 PMC: 4958915. DOI: 10.3389/fendo.2016.00103.

References

Morgenthaler N, Minich W, Willnich M, Bogusch T, Hollidt J, Weglohner W . Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum. Mol Cell Endocrinol. 2003; 212(1-2):73-9. DOI: 10.1016/j.mce.2003.09.018. View

Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly G . A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using.... Thyroid. 2010; 20(8):851-6. DOI: 10.1089/thy.2010.0059. View

Schott M, Morgenthaler N, Fritzen R, Feldkamp J, Willenberg H, Scherbaum W . Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res. 2004; 36(2):92-6. DOI: 10.1055/s-2004-814217. View

Saravanan P, Dayan C . Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001; 30(2):315-37, viii. DOI: 10.1016/s0889-8529(05)70189-4. View

Takasu N, Yamada T, Takasu M, Komiya I, Nagasawa Y, Asawa T . Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med. 1992; 326(8):513-8. DOI: 10.1056/NEJM199202203260803. View

Lytton S, Ponto K, Kanitz M, Matheis N, Kohn L, Kahaly G . A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010; 95(5):2123-31. DOI: 10.1210/jc.2009-2470. View

Lee J, Jang H, Kim S, Choi J, Kim J, Hur K . Diagnostic value of a chimeric TSH receptor (Mc4)-based bioassay for Graves' disease. Korean J Intern Med. 2011; 26(2):179-86. PMC: 3110850. DOI: 10.3904/kjim.2011.26.2.179. View

Kim T, Park Y, Park D, Chung H, Kim W, Kohn L . Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs. J Clin Endocrinol Metab. 2003; 88(1):117-24. DOI: 10.1210/jc.2002-020389. View

Ueta Y, Fukui H, Murakami H, Yamanouchi Y, Yamamoto R, Murao A . Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy. Thyroid. 1999; 9(2):179-82. DOI: 10.1089/thy.1999.9.179. View

10.

Nedrebo B, Holm P, Uhlving S, Sorheim J, Skeie S, Eide G . Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol. 2002; 147(5):583-9. DOI: 10.1530/eje.0.1470583. View

11.

Giuliani C, Cerrone D, Harii N, Thornton M, Kohn L, Dagia N . A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease. J Clin Endocrinol Metab. 2012; 97(7):E1106-15. DOI: 10.1210/jc.2011-2893. View

12.

Smith B . Thyroid autoantibodies. Scand J Clin Lab Invest Suppl. 2001; 235:45-52. DOI: 10.1080/003655101753352040. View

13.

DeLong E, Delong D, Clarke-Pearson D . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. View

14.

Maugendre D, Massart C . Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf). 2001; 54(1):89-96. DOI: 10.1046/j.1365-2265.2001.01197.x. View

15.

Schott M, Scherbaum W, Morgenthaler N . Thyrotropin receptor autoantibodies in Graves' disease. Trends Endocrinol Metab. 2005; 16(5):243-8. DOI: 10.1016/j.tem.2005.05.009. View

16.

Chen W, Man N, Li Y, Shan Z, Teng W . [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease]. Zhonghua Nei Ke Za Zhi. 2006; 45(2):95-9. View

17.

Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, OHSAWA N . Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Thyroid. 1999; 9(8):769-73. DOI: 10.1089/thy.1999.9.769. View

18.

Hedley A, Young R, Jones S, Alexander W, BEWSHER P . Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin Endocrinol (Oxf). 1989; 31(2):209-18. DOI: 10.1111/j.1365-2265.1989.tb01244.x. View

19.

Giuliani C, Cerrone D, Harii N, Thornton M, Kohn L, Dagia N . A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab. 2012; 97(7):E1080-7. DOI: 10.1210/jc.2011-2897. View

20.

Zophel K, Roggenbuck D, Schott M . Clinical review about TRAb assay's history. Autoimmun Rev. 2010; 9(10):695-700. DOI: 10.1016/j.autrev.2010.05.021. View